|
|
|
European Biopharmaceutical Review
|
Cellular therapies – such as treatment with mesenchymal stem cells (MSCs) or, recently, with genetically adapted T-autologous (Ta) cells – are coming of age and have exhibited their efficacy for selected indications in numerous preclinical trials. Many have received first approvals or are likely to in the near future. MSCs have been approved for selected indications in Canada as well as New Zealand, and at least one chimeric antigen receptor (CAR) T-cell product has gained a unanimous positive review by the FDA advisory committee.
The cross-section of medical devices and cellular therapies has been explored and utilised for some time; for example, cells have been embedded in collagenous foams to secure their location, or catheters have been employed to facilitate targeted delivery of cells.
For biologics and small molecules, this cross-section is perhaps not as clearly visible, yet it has transpired that combinations may yield massive improvements, as demonstrated in preclinical studies. Hence, this appears to be an opportunity worthy of exploration due to its benefits as well as its practical, quality and regulatory implications.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Bezyl, Inc. and THREAD Form Strategic Partnership to Support the Mental Health of Clinical Trial Participants
Bezyl’s digital health app aims to support the mental health of patients
by bringing the power of each patient’s network to the palm of the hand
More info >> |
|
 |
White Papers |
 |
|
The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing
GE Healthcare Life Sciences
For the past several years, the biopharma industry has been buffeted by
dynamic market conditions that are rapidly reshaping manufacturing
requirements. These factors include:
• The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model
• Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint
• The emergence of biosimilars and continued evolution of healthcare
reform, which will increasingly pressure drug pricing and require
greater cost discipline
• Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures
• Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >> |
|
|
